Advanced Viral Research (ADVR) Announces Results of Phase I Study on Type 2 Diabetes.

YONKERS, N.Y. -- Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) a bio-pharmaceutical company, announced today that following an interim analysis of 30 patients treated with a 4.0ml dose of AVR118, as well as an additional 3 patients treated with a 1.0ml dose, the company is satisfied in concluding that AVR 118 can be given safely to patients with Type 2 diabetes. Contrary to previous reports, AVR118 had no apparent effects on blood glucose levels in patients receiving oral hypoglycemic therapies. Moreover, AVR118 had no demonstrable effect on blood chemistry, hematology, weight gain or lean body mass. These findings reinforce the belief that AVR 118 is extremely well tolerated and has no apparent effect on glucose metabolism.

"The results of this study provide further evidence that AVR118 has a very innocuous side effect profile that should not preclude its use in patients unable to tolerate a sudden drop in blood sugar. Because AVR 118 had no effects on serum glucose levels, it appears we can avoid a potential contraindication in this potentially large population of patients with Type 2 Diabetes," says Stephen Elliston, President and CEO of Advanced Viral Research. "Based on this and other safety data, AVR 118 will now continue to advance into Phase II clinical testing to establish efficacy in an expanded list of targeted disease states," added Elliston.

Advanced Viral Research Corp is a New York based biopharmaceutical company dedicated to improving patients' lives by researching, developing and bringing to market new and effective therapies for the systematic control of symptoms associated with cancer and other serious diseases. ADVR's lead product, AVR118 represents a new class of complex cytoprotective agents that target among other things, cachexia related disorders. AVR118 has also shown to have topical wound healing properties in animal models.

Various degenerative conditions associated with body wasting (cachexia) such as cancer, HIV/AIDS and chronic inflammation are potential disease targets for AVR118 therapy.

Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by the Company. AVR118 (Product R) is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. There is no assurance that the Company will be able to secure the financing necessary to continue and/or complete the clinical trials of AVR118 or satisfy certain other conditions relating to clinical trials including obtaining adequate insurance on terms acceptable to the Company or that if completed, clinical trials performed outside the United States will assist the Company in obtaining FDA or other regulatory approval. The Company undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.

For further information regarding Advanced Viral Research Corp., please Visit our website at http://www.adviral.com.